株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

尿路サイクル異常症 (UCD) の世界市場:産業分析と将来展望

Urea Cycle Disorder (UCD) Market: Industry Analysis & Outlook (2019-2023)

発行 Koncept Analytics 商品コード 854707
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.72円で換算しております。
Back to Top
尿路サイクル異常症 (UCD) の世界市場:産業分析と将来展望 Urea Cycle Disorder (UCD) Market: Industry Analysis & Outlook (2019-2023)
出版日: 2019年06月01日 ページ情報: 英文 61 Pages
概要

当レポートでは、世界の尿路サイクル異常症 (UCD) 向け治療薬の市場について分析し、疾患の概要や市場構造・背景事情、全体的な市場規模の推定値・予測値 (今後5年間分)、地域別の詳細動向、主な市場促進・抑制要因、企業間の競争状態 (業績・製品比較)、主要企業のプロファイルといった情報を取りまとめてお届けいたします。

第1章 概要

  • 尿路サイクル
  • 尿路サイクルのプロセス
  • 尿路サイクル異常症 (UCD)
  • UCDの種類とその管理方法
  • UCDの診断・治療方法

第2章 米国市場の分析

  • 米国のUCD総患者数の予測
  • 米国のUCD既存/新規患者数
  • 米国の受診済みUCD患者数の予測
  • 米国のUCD治療薬市場
    • Ravicti:市場収益額
    • Ravicti:市場収益額の予測
    • KB195:市場収益額の予測
    • KB195で治療されたUCD患者数の予測

第3章 欧州市場の分析

  • 欧州のUCD総患者数の予測
  • 欧州のUCD既存/新規患者数
  • 欧州の受診済みUCD患者数の予測
  • 欧州のUCD治療薬市場
    • KB195:市場収益額の予測
    • KB195で治療されたUCD患者数の予測

第4章 市場のダイナミクス

  • 成長促進要因
  • 主な傾向と動静
  • 課題

第5章 競争環境

  • 主要企業:UCD関連の医薬品パイプライン
  • 主要企業:市場収益額の比較
  • 主要企業:株式時価総額の比較

第6章 企業プロファイル

  • Horizon Pharma Plc.
    • 事業概要
    • 主な財務指標
    • 事業戦略
  • Ultragenyx Pharmaceuticals Inc.
  • Aeglea Bio Therapeutics
  • Synlogix
目次

Urea cycle disorders (UCDs) are a group of orphan inherited defects of six enzymes and two transporters that constitute the urea cycle in the periportal liver cells. The age of onset symptoms vary between the different types of UCDs. UCDs often occurs during the period of infancy due to triggered postnatal catabolism. The diagnosis is made by analysis of the urine and blood for abnormal metabolites (substance produced by metabolism), and high ammonia levels. Frequent blood tests are done to monitor ammonia levels. The treatment of urea cycle disorders consists of dietary management to limit ammonia production. A liver transplant can be an effective treatment for urea cycle disorder for the proper functioning of urea cycle.

The urea cycle disorder treatment market in the U.S. and Europe is expected to grow rapidly in the next few years. Several pharmaceutical companies are under the development process of their late stage pipeline drugs for urea cycle disorders. Factors such as, increasing healthcare expenditures in the U.S, rise in the U.S. pharmaceutical R&D expenditures and collaboration between pharmaceutical companies and research institutes have driven the growth of the U.S. urea cycle disorder treatment market. Further, upcoming launches of anti-UCD drugs would contribute to the expansion of the urea cycle disorder treatment market in the U.S. as well as in Europe.

The U.S. urea cycle disorder treatment market is dominated by certain key players including Horizon Pharma Inc., Ultragenyx Pharmaceuticals Inc., Aeglea Bio Therapeutics and Synlogix. Among all the key players, Horizon Pharma ruled the U.S. UCD treatment market owing to the strong performance of its product. Horizon' Ravicti is the market leader due its strong curative impact on the patients with UCD. The remaining key players have their products under the development process of pipeline drugs for UCDs. There would be a generic competition between the upcoming anti-UCD drugs in the coming years.

Table of Contents

1. Overview

  • 1.1. Urea Cycle
  • 1.2. Process of Urea Cycle
  • 1.3. Urea Cycle Disorder (UCD)
  • 1.4. Types of UCDs and Their Management
  • 1.5. Diagnosis and Treatment of UCD

2. The U.S. Market Analysis

  • 2.1. The U.S. Total UCD Population Forecast
  • 2.2. The U.S. Existing and New UCD Population Forecast
  • 2.3. The U.S. Diagnosed UCD Population Forecast
  • 2.4. The U.S. UCD Drug Market
    • 2.4.1. The U.S. Ravicti Revenue
    • 2.4.2. The U.S. Ravicti Revenue Forecast
    • 2.4.3. The U.S KB195 Revenue Forecast
    • 2.4.4. The U.S. UCD Population Treated with KB195 Forecast

3. Europe Market Analysis

  • 3.1. Europe UCD Population Forecast
  • 3.2. Europe Existing and New UCD Population Forecast
  • 3.3. Europe Diagnosed UCD Population Forecast
  • 3.4. Europe UCD Drug Market
    • 3.4.1. Europe KB195 Revenue Forecast
    • 3.4.2. Europe UCD Population Treated with KB195 Forecast

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Increasing Healthcare Expenditure in the U.S.
    • 4.1.2. Rise in Pharmaceutical R&D Expenditures in the U.S.
    • 4.1.3. Collaboration of Pharmaceutical Companies with Research Institutes
  • 4.2. Key Trends and Development
    • 4.2.1. Shifts in the Newborn Population in the U.S. and Europe
    • 4.2.2. Upcoming Launches of Anti-UCD Drugs
    • 4.2.3. Development of Orphan Drugs for Urea Cycle Disorder
  • 4.3. Challenges
    • 4.3.1. Less Definitive Treatment Options
    • 4.3.2. High Healthcare and Medical Costs
    • 4.3.3. Stringent Medical Regulations

5. Competitive Landscape

  • 5.1. Key Players - Drugs Pipeline in the Urea Cycle Disorder Space
  • 5.2. Key Players - Revenue Comparison
  • 5.3. Key Players - Market Capital Comparison

6. Company Profiles

  • 6.1. Horizon Pharma Plc.
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Ultragenyx Pharmaceuticals Inc.
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Aeglea Bio Therapeutics
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Synlogix
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Figures

  • Urea Cycle
  • The U.S Total UCD Population Forecast (2019-2023)
  • The U.S Existing and New UCD Population Forecast (2019-2023)
  • The U.S Diagnosed UCD Population Forecast (2019-2023)
  • The U.S Ravicti Revenue (2014-2018)
  • The U.S Ravicti Revenue Forecast (2019-2023)
  • The U.S KB195 Revenue Forecast (2022-2026)
  • The U.S. UCD Population Treated with KB195 Forecast (2022-2026)
  • Europe UCD Population Forecast (2019-2023)
  • Europe Existing and New UCD Population Forecast (2019-2022)
  • Europe Diagnosed UCD Population Forecast (2019-2023)
  • Europe KB195 Revenue Forecast (2023-2027)
  • Europe UCD Population Treated with KB195 Forecast (2023-2027)
  • The U.S. Healthcare Expenditure per Capita (2014-2018)
  • Pharmaceutical R&D Expenditures in the U.S. (2014-2018)
  • The U.S and Europe Newborn Population Forecast (2019-2023)
  • Key Players - Market Capital Comparison
  • Horizon Pharma Plc. Revenue by Segment (2018)
  • Horizon Pharma Plc. Revenue and Net Loss (2014-2018)
  • Horizon Pharma Plc. R&D Expenditure (2016-2018)
  • Horizon Pharma Plc. Advertising Expenditure (2016-2018)
  • Ultragenyx Pharmaceuticals Revenue by Segment (2018)
  • Ultragenyx Pharmaceuticals Revenue and Net Loss (2014-2018)
  • Ultragenyx Pharmaceuticals R&D Expenditure (2016-2018)
  • Aeglea Bio Therapeutics Revenue and Net Loss (2014-2018)
  • Aeglea Bio Therapeutics R&D Expenditure (2016-2018)
  • Synlogix Revenue and Net Loss (2014-2018)
  • Synlogix R&D Expenditure (2016-2018)

List of Tables

  • Types of UCDs and Their Management
  • Upcoming Launches of Anti-UCD Drugs
  • Regulations and Policies for Orphan Drugs
  • Key Players - Product Pipeline in the Urea Cycle Disorder Space
  • Key Players - Revenue Comparison (2018)
  • Aeglea Bio Therapeutics Drugs Pipeline Overview (2018)
  • Synlogix Drugs Pipeline Overview (2018)
Back to Top